Welcome to the
Biogen Newsroom

Find out how we are pioneering neuroscience to transform lives and support our communities by exploring the latest news releases, Biogen initiatives, company statements and exclusive stories.

Latest News

October 20, 2021
Biogen Reports Third Quarter 2021 Results
October 19, 2021
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

Following the pre-NDA meeting, the companies confirmed t he current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD The planned initial submission package will be for the treatment of MDD with an anticipated PPD filing thereafter

October 17, 2021
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed The

See Our Latest Tweets

Biogen Statements
Biogen Statements

See the latest news and statements from Biogen to stay up to date on our progress and learn about new company initiatives.

Read More
Annual Report
Annual Report

Review our annual reports to see performance highlights, financials, SEC filings, stock information and more.

Read More
Sustainability Report
Sustainability Report: 2020 Year in Review

Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.

Read More

Innovation in Alzheimer's

We remain focused on furthering Alzheimer’s disease research and treatment. Explore the latest information, news and stories about Alzheimer’s disease at Biogen.

Alzheimer

The Alzheimer’s Puzzle: Unlocking the Science

From imaging that enables us to see amyloid and tau in the brain and determine whether potential therapeutics reach their targets, to one big leap of faith that antibodies can get into the brain, our scientists are not giving up on solving the Alzheimer’s puzzle.

health
Healthy Climate, Healthy Lives™

Biogen invests $250 million in a 20-year initiative to accelerate action on the greatest challenges of our time: climate, health and equity.

Read More
Diversity
Diversity, Equity and Inclusion

We are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients who we serve.

Read More
Corporate Responsibility

Our Commitment to Corporate Responsibility

Our impact goes beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, and help our employees thrive.

Read More

Request Multimedia Resources

For Media Professionals

Access Biogen logos, infographics, images, videos and more. Our media relations team will help you find exactly what you need.

Get in Touch

Get Biogen Updates Delivered to Your Inbox

Subscribe to receive news and stories from Biogen that reflect both our dedication to transforming lives through pioneering neuroscience as well as our commitment to our communities.”

Sign Up for Biogen Alerts
Be the first to know about the latest news, updates, events and SEC Filings by signing up for Biogen email alerts.